Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: sds who wrote (2559)	5/6/1999 2:11:00 AM
From: tom jones	Read Replies (1) \| Respond to of 4676

To all: Upbeat comments in the first quarter earnings press release. biz.yahoo.com 2302 will finish it's trial near the end of 1999 and interim analysis looks ok. I talked with investor relations and was told their would be no press release or presentation of this interim analysis. All patients in the trial have not started so that is why there is no set date for completion. 2302 phase II for kidney transplant rejection completion in the second half of 1999, Some of the phase II trials of 3521 and 5132 will finish near the end of 1999. Preliminary data from the phase II trials shows potential. 3521 preliminary data will be presented at the American Society of Clinical Oncology. Was told this will be a poster and should also be a press release from Isis. Maybe we will have a very nice Christmas or have I said that before? Tom